ArticleAnales del sistema sanitario de Navarra2025
[Clinical response to brivaracetam in two cases of drug-resistant juvenile absence epilepsy].
Article in Anales del sistema sanitario de Navarra, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although only around 20% of individuals with idiopathic generalized epilepsy are drug-resistant, this minority presents a significant therapeutic challenge due to the limited number of approved medications for this condition. For absence seizures, only valproic acid and ethosuximide are approved by both the U.S. Food and Drug administration and the European Medicines Agency, with lamotrigine additionally approved by the European Medicines Agency. Evidence supporting the use of levetiracetam in this seizure type is limited, and brivaracetam has not yet been approved for generalized epilepsy. We report two cases of juvenile absence epilepsy in women with incomplete response and intolerance to first-line treatments, who demonstrated marked clinical improvement following treatment with brivaracetam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.